- Home
- NXTT vs APRE Comparison
NXTT vs APRE Comparison
Compare NXTT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTT
- APRE
- Stock Information
- Founded
- NXTT 2019
- APRE 2006
- Country
- NXTT China
- APRE United States
- Employees
- NXTT N/A
- APRE N/A
- Industry
- NXTT
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXTT
- APRE Health Care
- Exchange
- NXTT NYSE
- APRE Nasdaq
- Market Cap
- NXTT 16.8M
- APRE 15.8M
- IPO Year
- NXTT N/A
- APRE 2019
- Fundamental
- Price
- NXTT $2.82
- APRE $3.85
- Analyst Decision
- NXTT
- APRE Strong Buy
- Analyst Count
- NXTT 0
- APRE 2
- Target Price
- NXTT N/A
- APRE $15.50
- AVG Volume (30 Days)
- NXTT 55.0K
- APRE 33.0K
- Earning Date
- NXTT 11-15-2024
- APRE 11-07-2024
- Dividend Yield
- NXTT N/A
- APRE N/A
- EPS Growth
- NXTT N/A
- APRE N/A
- EPS
- NXTT 3.59
- APRE N/A
- Revenue
- NXTT $1,133,308.00
- APRE $1,310,839.00
- Revenue This Year
- NXTT N/A
- APRE $134.21
- Revenue Next Year
- NXTT N/A
- APRE N/A
- P/E Ratio
- NXTT $0.80
- APRE N/A
- Revenue Growth
- NXTT N/A
- APRE 130.31
- 52 Week Low
- NXTT $0.94
- APRE $2.15
- 52 Week High
- NXTT $6.66
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- NXTT 58.28
- APRE 56.63
- Support Level
- NXTT $2.27
- APRE $3.34
- Resistance Level
- NXTT $2.80
- APRE $3.83
- Average True Range (ATR)
- NXTT 0.39
- APRE 0.42
- MACD
- NXTT -0.03
- APRE 0.01
- Stochastic Oscillator
- NXTT 54.69
- APRE 36.04
About NXTT NEXT TECHNOLOGY HOLDING INC
Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.